Amyloid Light Chain Amyloidosis clinical trials

Explore recruiting amyloid light chain amyloidosis clinical trials.

Recruiting amyloid light chain amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Amyloid Light Chain Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL)

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Germany, France, Spain, Netherlands, Italy, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone) in Untreated Patients with Light Chain Amyloidosis

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

Italy, Greece, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

Hungary, Belgium, Spain, Czechia, Italy, Greece

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase II Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis

Greece, Italy, France, Germany, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Amyloid Light Chain Amyloidosis trials by city

Amyloid Light Chain Amyloidosis in Toronto Amyloid Light Chain Amyloidosis in Vancouver Amyloid Light Chain Amyloidosis in Montreal Amyloid Light Chain Amyloidosis in Calgary Amyloid Light Chain Amyloidosis in Edmonton Amyloid Light Chain Amyloidosis in Ottawa Amyloid Light Chain Amyloidosis in Winnipeg Amyloid Light Chain Amyloidosis in Quebec City Amyloid Light Chain Amyloidosis in Hamilton Amyloid Light Chain Amyloidosis in Kitchener Amyloid Light Chain Amyloidosis in London Amyloid Light Chain Amyloidosis in Halifax Amyloid Light Chain Amyloidosis in New York Amyloid Light Chain Amyloidosis in Los Angeles Amyloid Light Chain Amyloidosis in Chicago Amyloid Light Chain Amyloidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease